|
GB9414139D0
(en)
|
1994-07-13 |
1994-08-31 |
Smithkline Beecham Plc |
Novel compounds
|
|
WO1997027852A1
(en)
|
1996-01-30 |
1997-08-07 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
EE200000522A
(et)
|
1998-02-25 |
2002-02-15 |
Genetics Institute, Inc. |
Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
|
|
US6316503B1
(en)
|
1999-03-15 |
2001-11-13 |
Tularik Inc. |
LXR modulators
|
|
EP1212065A4
(en)
|
1999-07-08 |
2004-02-11 |
Tularik Inc |
COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL
|
|
JP2004507456A
(ja)
|
2000-05-11 |
2004-03-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
|
|
US6777446B2
(en)
|
2000-09-05 |
2004-08-17 |
Tularik, Inc. |
FXR modulators
|
|
US7256201B2
(en)
|
2000-12-07 |
2007-08-14 |
Astrazeneca Ab |
Selective estrogen receptor-β ligands
|
|
WO2002058690A2
(en)
|
2001-01-26 |
2002-08-01 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
|
|
US6649606B1
(en)
|
2001-11-09 |
2003-11-18 |
Bristol-Myers Squibb Co. |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
|
AU2003220521A1
(en)
|
2002-03-27 |
2003-10-13 |
Smithkline Beecham Corporation |
Methods of treatment with lxr modulators
|
|
EP1501867A1
(en)
|
2002-04-29 |
2005-02-02 |
Novartis AG |
Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
|
|
US20060189693A1
(en)
|
2003-07-22 |
2006-08-24 |
Barone Frank C |
Methods of treatment with lxr agonists
|
|
EP1653938A2
(en)
|
2003-07-28 |
2006-05-10 |
Glaxo Group Limited |
Methods of treatment of inflammatory bowel disease with lxr agonists
|
|
WO2005055998A1
(en)
|
2003-12-04 |
2005-06-23 |
Smithkline Beecham Corporation |
Methods of treatment with lxr agonists
|
|
WO2006091862A2
(en)
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Cytokine inhibitors and their use in therapy
|
|
WO2007058990A2
(en)
|
2005-11-14 |
2007-05-24 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
|
WO2007055374A1
(ja)
|
2005-11-14 |
2007-05-18 |
Mitsubishi Tanabe Pharma Corporation |
骨粗鬆症治療剤
|
|
PE20071025A1
(es)
|
2006-01-31 |
2007-10-17 |
Mitsubishi Tanabe Pharma Corp |
Compuesto amina trisustituido
|
|
AR059826A1
(es)
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
|
EP2035005A4
(en)
|
2006-06-09 |
2011-07-06 |
Kemia Inc |
THERAPY BASED ON CYTOKINE INHIBITORS
|
|
CN101490002A
(zh)
|
2006-07-12 |
2009-07-22 |
阿斯利康(瑞典)有限公司 |
作为止痛剂的3-氧代异二氢吲哚-1-甲酰胺衍生物
|
|
TW200812962A
(en)
|
2006-07-12 |
2008-03-16 |
Astrazeneca Ab |
New compounds I/418
|
|
US8648096B2
(en)
|
2006-09-15 |
2014-02-11 |
Celgene Corporation |
N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
|
|
JP4846769B2
(ja)
|
2007-07-30 |
2011-12-28 |
田辺三菱製薬株式会社 |
医薬組成物
|
|
JP4834699B2
(ja)
|
2007-07-30 |
2011-12-14 |
田辺三菱製薬株式会社 |
医薬組成物
|
|
WO2011115892A1
(en)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
|
WO2012028100A1
(en)
|
2010-09-01 |
2012-03-08 |
Glaxo Group Limited |
Novel compounds
|
|
WO2012027965A1
(en)
|
2010-09-01 |
2012-03-08 |
Glaxo Group Limited |
Novel compounds
|
|
WO2012100734A1
(en)
|
2011-01-24 |
2012-08-02 |
Glaxo Group Limited |
Compounds useful as retinoid-related orphan receptor gamma modulators
|
|
WO2012100732A1
(en)
|
2011-01-24 |
2012-08-02 |
Glaxo Group Limited |
Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
|
|
EP2487159A1
(en)
|
2011-02-11 |
2012-08-15 |
MSD Oss B.V. |
RorgammaT inhibitors
|
|
WO2012158784A2
(en)
|
2011-05-16 |
2012-11-22 |
Theodore Mark Kamenecka |
Modulators of the nuclear hormone receptor ror
|
|
WO2013029338A1
(en)
|
2011-09-01 |
2013-03-07 |
Glaxo Group Limited |
Novel compounds
|
|
WO2013100027A1
(ja)
|
2011-12-28 |
2013-07-04 |
武田薬品工業株式会社 |
複素環化合物
|
|
US9365512B2
(en)
|
2012-02-13 |
2016-06-14 |
AbbVie Deutschland GmbH & Co. KG |
Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
|
|
WO2013159095A1
(en)
|
2012-04-20 |
2013-10-24 |
Anderson Gaweco |
Ror modulators and their uses
|
|
WO2013166013A1
(en)
|
2012-04-30 |
2013-11-07 |
Anderson Gaweco |
Ror modulators and their uses
|
|
EP2844260A4
(en)
|
2012-04-30 |
2016-06-29 |
Anderson Gaweco |
ROR MODULATORS AND ITS USES
|
|
WO2013171729A2
(en)
|
2013-01-08 |
2013-11-21 |
Glenmark Pharmaceuticals S.A. |
Aryl and heteroaryl amide compounds as rorgamat modulator
|
|
WO2014125426A1
(en)
|
2013-02-15 |
2014-08-21 |
Aurigene Discovery Technologies Limited |
Trisubstituted heterocyclic derivatives as ror gamma modulators
|
|
US10005720B2
(en)
|
2013-04-05 |
2018-06-26 |
North Carolina Central University |
Compounds useful for the treatment of metabolic disorders and synthesis of the same
|
|
EP2991994B1
(en)
|
2013-05-01 |
2018-08-15 |
Vitae Pharmaceuticals, Inc. |
Thiazolopyrrolidine inhibitors of ror-gamma
|
|
JP6411342B2
(ja)
|
2013-07-03 |
2018-10-24 |
武田薬品工業株式会社 |
アミド化合物
|
|
EP3018126A4
(en)
|
2013-07-03 |
2016-12-07 |
Takeda Pharmaceuticals Co |
HETEROCYCLIC CONNECTION
|
|
EP3027616B1
(en)
|
2013-07-30 |
2018-01-10 |
Boehringer Ingelheim International GmbH |
Azaindole compounds as modulators of rorc
|
|
WO2015035032A1
(en)
|
2013-09-05 |
2015-03-12 |
Boehringer Ingelheim International Gmbh |
Bicylic compounds as modulators of rorgamma
|
|
WO2015082533A1
(en)
|
2013-12-05 |
2015-06-11 |
Lead Pharma Cel Models Ip B.V. |
Ror gamma (rory) modulators
|
|
WO2015083130A1
(en)
|
2013-12-06 |
2015-06-11 |
Aurigene Discovery Technologies Limited |
Fused pyridine and pyrimidine derivatives as ror gamma modulators
|
|
WO2015101928A1
(en)
|
2013-12-31 |
2015-07-09 |
Aurigene Discovery Technologies Limited |
Fused thiophene and thiazole derivatives as ror gamma modulators
|
|
DK3102576T3
(da)
|
2014-02-03 |
2019-07-22 |
Vitae Pharmaceuticals Llc |
Dihydropyrrolopyridininhibitorer af ror-gamma
|
|
WO2015129853A1
(ja)
|
2014-02-27 |
2015-09-03 |
東レ株式会社 |
環状アミン誘導体及びその医薬用途
|
|
CA2942871A1
(en)
|
2014-03-27 |
2015-10-01 |
Piramal Enterprises Limited |
Ror-gamma modulators and uses thereof
|
|
BR122020020657B1
(pt)
|
2014-04-14 |
2022-12-20 |
Boehringer Ingelheim International Gmbh |
Compostos, composição farmacêutica e seus usos como moduladores de ror gama
|
|
CA2940264A1
(en)
|
2014-04-16 |
2015-10-22 |
Glenmark Pharmaceuticals S.A. |
Aryl and heteroaryl ether compounds as ror gamma modulators
|
|
US9365520B2
(en)
|
2014-07-01 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
MY195016A
(en)
|
2014-08-04 |
2023-01-03 |
Nuevolution As |
Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
|
|
MA40759A
(fr)
|
2014-09-26 |
2017-08-01 |
Pfizer |
Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
|
|
SI3207043T1
(sl)
|
2014-10-14 |
2019-04-30 |
Vitae Pharmaceuticals, Inc. |
Dihidropirolopiridinovi inhibitorji za ROR-gama
|
|
US9845308B2
(en)
|
2014-11-05 |
2017-12-19 |
Vitae Pharmaceuticals, Inc. |
Isoindoline inhibitors of ROR-gamma
|
|
US9663515B2
(en)
|
2014-11-05 |
2017-05-30 |
Vitae Pharmaceuticals, Inc. |
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
JP2017538676A
(ja)
|
2014-11-05 |
2017-12-28 |
ザ ユニバーシティ オブ カンザス |
ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤
|
|
US20180110774A1
(en)
|
2015-04-28 |
2018-04-26 |
Stc. Unm |
Compositions and methods for treatment of pulmonary hypertension
|
|
KR102702236B1
(ko)
|
2015-05-15 |
2024-09-04 |
오리진 온콜로지 리미티드 |
Ror 감마 조절제로서의 치환된 테트라하이드로퀴놀리논 화합물
|
|
EP3101009A1
(en)
|
2015-06-05 |
2016-12-07 |
Lead Pharma Cel Models IP B.V. |
Ror gamma (rory) modulators
|
|
EP3101008A1
(en)
|
2015-06-05 |
2016-12-07 |
Lead Pharma Cel Models IP B.V. |
Ror gamma (rory) modulators
|
|
EP3101005A1
(en)
|
2015-06-05 |
2016-12-07 |
Lead Pharma Cel Models IP B.V. |
Ror gamma (rory) modulators
|
|
EP3101007A1
(en)
|
2015-06-05 |
2016-12-07 |
Lead Pharma Cel Models IP B.V. |
Ror gamma (rory) modulators
|
|
EP3101006A1
(en)
|
2015-06-05 |
2016-12-07 |
Lead Pharma Cel Models IP B.V. |
Ror gamma (rory) modulators
|
|
WO2017010399A1
(ja)
|
2015-07-10 |
2017-01-19 |
塩野義製薬株式会社 |
ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物
|
|
EP3331876B1
(en)
|
2015-08-05 |
2020-10-07 |
Vitae Pharmaceuticals, LLC |
Modulators of ror-gamma
|
|
US10450314B2
(en)
|
2015-10-01 |
2019-10-22 |
Boehringer Ingelheim International Gmbh |
Pteridine derivatives as modulators of ROR gamma
|
|
KR101947976B1
(ko)
|
2015-12-15 |
2019-02-13 |
아스트라제네카 아베 |
이소인돌 화합물
|